M&A / Property Routine +

Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada

Medexus adds late-stage cell therapy to pipeline, but near-term value remains tethered to GRAFAPEX commercialization ramp

By The Northwire Desk — AI Analysis Jun 09, 2026 · 17:31 MDP · 4.03 MEDEXUS PHARMACEUTICALS INC. J

Executive Summary

Medexus Pharmaceuticals secured exclusive Canadian commercial rights to UM171 Cell Therapy (Zemcelpro®), a personalized hematopoietic stem cell transplantation product conditionally approved in Europe.
The transaction structure includes a $2 million initial payment to Cordex Biologics, quarterly royalties on net sales to ExCellThera, and various milestone payments. Medexus will sponsor the Health Canada New Drug Submission.
Zemcelpro® targets hematological malignancies requiring allo-HSCT. Phase 2 data (60 patients) demonstrated a 63.7% 24-month overall survival rate.
Commercialization in Canada is not expected before calendar year 2028, potentially 2031 depending on regulatory pathways.
The $2 million initial payment is funded entirely via the delayed draw term loan feature of Medexus's existing senior secured credit facility with National Bank of Canada.
Management states the deal is a strategic fit with existing hemato-oncology product treosulfan (GRAFAPEX) and will not significantly impact near-term capital allocation.

Material Impact

The UM171 license is a strategic pipeline add-on for the Canadian market, but commercialization is not expected until 2028. It does not change near-term revenue or cash flow profiles.
The stock's +40.6% run into this print implies the market has already priced in the GRAFAPEX ramp and credit facility success.
The news is Routine - Positive. It extends the franchise and validates management's hemato-oncology strategy, but lacks the immediacy or scale to re-rate the business. The market reaction will likely be muted, as the core value driver remains the GRAFAPEX commercial execution.

MDP · Price

Company Overview

Medexus Pharmaceuticals is a biopharmaceutical company focused on hemato-oncology and cell therapy.
Core product: GRAFAPEX (treosulfan) for injection, launched in the US in February 2025.
Pipeline: UM171 Cell Therapy (Zemcelpro®) licensed for Canada.
Financial profile: Transitioning from legacy generic erosion to new product commercialization. Strong balance sheet with low leverage and positive operating cash flow.

More from MEDEXUS PHARMACEUTICALS INC. J